PAVmed (NASDAQ:PAVM) Upgraded to “Sell” at Wall Street Zen

PAVmed (NASDAQ:PAVM) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

A number of other equities analysts also recently issued reports on PAVM. Ascendiant Capital Markets reduced their price target on PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a research report on Wednesday, December 10th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research report on Thursday, January 22nd. Finally, Zacks Research lowered PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $510.00.

PAVmed Stock Up 1.7%

Shares of PAVmed stock opened at $10.45 on Friday. The company has a market cap of $10.24 million, a P/E ratio of -0.61 and a beta of 1.12. The firm’s 50 day moving average price is $8.97 and its 200-day moving average price is $11.61. PAVmed has a 52-week low of $6.00 and a 52-week high of $28.44.

Institutional Trading of PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC grew its position in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. 19.93% of the stock is owned by hedge funds and other institutional investors.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.